Cargando…
In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
BACKGROUND: The objective of this study was to characterize the in vitro and in vivo properties of the F(ab')(2 )fragment of panitumumab and to investigate its potential for imaging and radioimmunotherapy. METHODS: The panitumumab F(ab')(2 )was generated by enzymatic pepsin digestion. Afte...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155408/ https://www.ncbi.nlm.nih.gov/pubmed/21845232 http://dx.doi.org/10.1186/2191-219X-1-1 |
_version_ | 1782210119815135232 |
---|---|
author | Wong, Karen J Baidoo, Kwamena E Nayak, Tapan K Garmestani, Kayhan Brechbiel, Martin W Milenic, Diane E |
author_facet | Wong, Karen J Baidoo, Kwamena E Nayak, Tapan K Garmestani, Kayhan Brechbiel, Martin W Milenic, Diane E |
author_sort | Wong, Karen J |
collection | PubMed |
description | BACKGROUND: The objective of this study was to characterize the in vitro and in vivo properties of the F(ab')(2 )fragment of panitumumab and to investigate its potential for imaging and radioimmunotherapy. METHODS: The panitumumab F(ab')(2 )was generated by enzymatic pepsin digestion. After the integrity and immunoreactivity of the F(ab')(2 )was evaluated, the fragment was radiolabeled. In vivo studies included direct quantitation of tumor targeting and normal organ distribution of the radiolabeled panitumumab F(ab')(2 )as well as planar γ-scintigraphy and PET imaging. RESULTS: The panitumumab F(ab')(2 )was successfully produced by peptic digest. The F(ab')(2 )was modified with the CHX-A"-DTPA chelate and efficiently radiolabeled with either (111)In or (86)Y. In vivo tumor targeting was achieved with acceptable uptake of radioactivity in the normal organs. The tumor targeting was validated by both imaging modalities with good visualization of the tumor at 24 h. CONCLUSIONS: The panitumumab F(ab')(2 )fragment is a promising candidate for imaging of HER1-positive cancers. |
format | Online Article Text |
id | pubmed-3155408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer |
record_format | MEDLINE/PubMed |
spelling | pubmed-31554082011-12-29 In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers Wong, Karen J Baidoo, Kwamena E Nayak, Tapan K Garmestani, Kayhan Brechbiel, Martin W Milenic, Diane E EJNMMI Res Original Research BACKGROUND: The objective of this study was to characterize the in vitro and in vivo properties of the F(ab')(2 )fragment of panitumumab and to investigate its potential for imaging and radioimmunotherapy. METHODS: The panitumumab F(ab')(2 )was generated by enzymatic pepsin digestion. After the integrity and immunoreactivity of the F(ab')(2 )was evaluated, the fragment was radiolabeled. In vivo studies included direct quantitation of tumor targeting and normal organ distribution of the radiolabeled panitumumab F(ab')(2 )as well as planar γ-scintigraphy and PET imaging. RESULTS: The panitumumab F(ab')(2 )was successfully produced by peptic digest. The F(ab')(2 )was modified with the CHX-A"-DTPA chelate and efficiently radiolabeled with either (111)In or (86)Y. In vivo tumor targeting was achieved with acceptable uptake of radioactivity in the normal organs. The tumor targeting was validated by both imaging modalities with good visualization of the tumor at 24 h. CONCLUSIONS: The panitumumab F(ab')(2 )fragment is a promising candidate for imaging of HER1-positive cancers. Springer 2011-06-07 /pmc/articles/PMC3155408/ /pubmed/21845232 http://dx.doi.org/10.1186/2191-219X-1-1 Text en Copyright © 2011 Wong et al; licensee Springer. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | Original Research Wong, Karen J Baidoo, Kwamena E Nayak, Tapan K Garmestani, Kayhan Brechbiel, Martin W Milenic, Diane E In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers |
title | In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers |
title_full | In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers |
title_fullStr | In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers |
title_full_unstemmed | In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers |
title_short | In vitro and in vivo pre-clinical analysis of a F(ab')(2 )fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers |
title_sort | in vitro and in vivo pre-clinical analysis of a f(ab')(2 )fragment of panitumumab for molecular imaging and therapy of her1-positive cancers |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155408/ https://www.ncbi.nlm.nih.gov/pubmed/21845232 http://dx.doi.org/10.1186/2191-219X-1-1 |
work_keys_str_mv | AT wongkarenj invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers AT baidookwamenae invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers AT nayaktapank invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers AT garmestanikayhan invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers AT brechbielmartinw invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers AT milenicdianee invitroandinvivopreclinicalanalysisofafab2fragmentofpanitumumabformolecularimagingandtherapyofher1positivecancers |